Recursion Pharmaceuticals (RXRX) Cash Flow: Operating & Free Cash Flow

Recursion Pharmaceuticals Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Recursion Pharmaceuticals, Inc. (RXRX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Operating Activities
Net Income	-644.76	-463.66	-328.07	-239.48	-186.48	-87.01	-61.88
Depreciation & Amortization	83.70	36.49	24.40	11.76	8.41	3.94	2.49
Deferred Income Tax	0.00	0.00	0.00	0.00	0.83	0.00	0.00
Stock Based Compensation	111.22	81.69	53.50	27.91	14.84	4.29	1.39
Change in Working Capital	13.69	-38.00	-50.26	104.92	-0.31	30.83	0.41
Change in Accounts Receivable	32.94	-6.07	-7.76	0.00	0.11	-1.12	0.61
Change in Inventory	0.00	0.00	0.00	0.00	7.84	0.00	0.00
Change in Accounts Payable	-2.62	6.44	-0.99	1.77	1.75	-0.19	-0.34
Change in Other Working Capital	-16.64	-38.37	-11.62	8.56	-10.00	32.14	0.14
Other Operating Activities	64.34	24.31	6.64	8.56	4.10	2.54	0.56
Net Cash from Operating Activities	-371.81	-359.17	-287.78	-83.52	-158.61	-45.40	-57.04
Investing Activities
Capital Expenditures	-6.47	-13.70	-11.96	-37.36	-39.80	-6.74	-3.91
Acquisitions	0.00	277.10	1.84	0.00	231.95	-2.60	0.00
Purchases of Investments	-3.81	0.00	0.48	0.00	-301.14	0.00	0.00
Sales/Maturities of Investments	0.00	0.00	0.48	230.61	69.19	0.00	0.00
Other Investing Activities	-6.60	-3.35	1.84	-0.30	-231.95	-0.31	0.00
Net Cash from Investing Activities	-16.87	260.06	-10.23	193.25	-271.74	-8.74	-3.91
Financing Activities
Debt Repayment	-8.43	-4.44	-0.77	-0.09	-12.80	6.32	0.71
Common Stock Issued	532.96	300.42	140.90	143.71	462.90	0.00	0.00
Other Financing Activities	-3.00	8.14	12.81	10.72	8.44	239.81	119.71
Net Cash from Financing Activities	521.53	304.12	140.13	154.35	458.54	246.14	120.41
Summary
Effect of Forex Changes on Cash	18.04	-3.41	0.19	-0.31	0.00	0.00	0.00
Net Change in Cash	150.90	201.60	-157.69	263.76	28.18	192.00	59.46
Cash at Beginning of Period	603.02	401.43	559.11	295.35	267.17	75.17	15.71
Cash at End of Period	753.92	603.02	401.43	559.11	295.35	267.17	75.17
Free Cash Flow	-378.28	-372.87	-299.74	-120.88	-198.41	-52.13	-60.95
Supplemental Disclosures
Interest Paid	-	-	-	-	0.68	0.99	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Recursion Pharmaceuticals Cash Flow

What is Recursion Pharmaceuticals's free cash flow?

Recursion Pharmaceuticals had negative free cash flow of $378.28M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$371.81M minus $6.47M of capital expenditures.

How much does Recursion Pharmaceuticals spend on capital expenditures?

Recursion Pharmaceuticals spent $6.47M on capital expenditures in fiscal 2025, compared with $13.70M a year earlier.

Does Recursion Pharmaceuticals pay dividends or buy back shares?

Recursion Pharmaceuticals's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition